News
We send the latest information from SMC Laboratories.
Amplia Therapeutics has publshed a pres releaes regarding the AMP945 and AMP886 efficacy evaluation study for NASH we have provied.
Amplia Therapeutics, which is our client, has announced the results of pharmacology study using a STAM™ mouse model. For detail information, see the Amplia's press release. https://www.ampliatx.com/site/PDF/fd3f2d1f-9d2b-4fff-a6ad-13a3ea8d4956/ATXFAKInhibitorsReduceFibrosisinAnimalModelofNASH
Chemomab announces enrollment of first patient in phase 2a study of CM-101 in NASH
Chemomab Ltd.(Israel) announced on 26 April, 2021, enrollment of first patient in phase 2a study of CM-101 in NASH. For detailed information, see the below URL. https://www.prnewswire.com/news-releases/chemomab-announces-enrollment-of-first-patient-in-phase-2a-study-of-cm-101-in-non-alcoholic-steatohepatitis-nash-301276524.html?tc=eml_cleartime CM-101, a monoclonal antibody designed to bind and block CCL24 activity. The antibody used the STAM™ mouse model for non-clinical studies, and data showing the improvement…
Pre-clinical studies for cirrhosis: Carbon tetrachloride (CCl4)-induced liver fibrosis
The CCl4-induced liver fibrosis model is a model that forms bridging fibrosis around the portal vein region. While our STAM™ model develops mild liver fibrosis, the CCl4 model develops severe cirrhosis-like fibrosis. We also offer pharmacological studies with the positive control ”Valsartan”. As its study period is relatively short, only 4 weeks, the model…
Wnt/β-catenin in our NASH-HCC model: How does it correlate to human liver cancer?
The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection. By virtue of recent advances in treatment methods, the number of patients with HCC caused by these infections is expected to decrease in the future. On the other hand, the number of patients with NAFLD and NASH is…
CohBar, Inc. announces the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesiy.
CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesity. For detail information, see the CohBar's press release. https://www.cohbar.com/news-media/press-releases/detail/143/cohbar-completes-enrollment-in-the-phase-1b-clinical-trial CB4211 is a first-in-class mitochondria based therapeutic. The peptide used the STAM™ mouse model for non-clinical studies,…
Positive control for UUO kidney fibrosis
We are excited to share with you an update about a newly established positive control – an ALK5 inhibitor – for our UUO-induced renal fibrosis model. This ALK5 inhibitor has an inhibitory effect on the TGF-beta/ALK5 signaling pathway, which plays a central role in renal fibrosis. Below is the result of fibrosis analysis from…
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-b Agonist ASC41
Gannex (Shanghai, China) has announced positive clinical results in overweigth and obse subjects for its THR-b agonist ASC41. For detail information, see the Gannex's press release. https://www.ascletis.com/news_detail/175/id/462.html
TERNS announces FDA clearance of investigational new drug application for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH
TERNS Pharmaceuticals, Inc. (USA) has announced FDA clearance of investigational new drug aplication for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH. For detail information, see the TERNS's press release. https://ir.ternspharma.com/news-releases/news-release-details/terns-announces-fda-clearance-investigational-new-drug-ind
Inventiva announces design of Phase III clinical trial with Ianifibranor in NASH
Inventiva (France) has announced design of Phase III clinical trial with Ianifibranor in NASH For detail information, see the Inventiva's press release. https://www.globenewswire.com/news-release/2021/01/05/2153793/0/en/Inventiva-announces-design-of-Phase-III-clinical-trial-with-lanifibranor-in-NASH.html
Hepion pharma announces positive top line data for low dose CRV431 in Phase 2a "AMBITION' clinical trial for treatment of advanced NASH.
Hepion pharma (NJ), which is our client, has announced positive top line data for low dose CRV431 in Phase 2a “AMBITION” clincal trial for treatment of advanced NASH. CRV431 is a cyclophillin inhibitor. The compound has been used in nonclinical pharmacology study using the STAMTM mouse model and has been shown to improve liver…